Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 04, 2023 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP Chief Patient & Ext Af Off | July 21, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
VERTEX PHARMACEUTICALS INC / MA
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,512 |
Reported balance
After 2026-07-21 transaction · row 1
1 source rowRow 1 · 2026-07-21 · Grant · Acquired 8,251 · Balance 66,512 F1: Restricted stock unit award that vests on 03/31/2030. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 882 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 882 |
| Common StockSEC Table I · non-derivative | IndirectHeld in Trust | 6,637 |
Reported balance
Holding disclosure · report date 2026-07-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,637 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award that vests on 03/31/2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2012 Filed Sep 17, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18,637 | $56.50 | $1,052,990.50 |
DisclosureSEC source: 0001209191-12-045738 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,108 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $56.50 (range $56.25 to $57.02). Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,644 | $55.86 | $1,097,313.84 |
DisclosureSEC source: 0001209191-12-045738 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,745 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $55.86 (range $55.25 to $56.23). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 9,531 | $32.16 | $306,516.96 |
DisclosureSEC source: 0001209191-12-045738 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 18,750 | $29.25 | $548,437.50 |
DisclosureSEC source: 0001209191-12-045738 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2012 Filed Jul 26, 2012 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-12-039160 · doc4.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/25/2012. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 56,250 | $0.00 Strike: $29.25 | $0.00 |
DisclosureSEC source: 0001209191-12-027019 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 56,250 shares Expires 2017-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 58,750 | $52.13 | $3,062,637.50 |
DisclosureSEC source: 0001209191-12-027019 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,108 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 56,250 | $29.25 | $1,645,312.50 |
DisclosureSEC source: 0001209191-12-027019 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 15:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 19,062 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-12-021005 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,062 shares Expires 2018-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 15:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 26,562 | $41.01 | $1,089,307.62 |
DisclosureSEC source: 0001209191-12-021005 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,608 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $41.01 (range $40.59 to $41.34). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 15:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 19,062 | $18.93 | $360,843.66 |
DisclosureSEC source: 0001209191-12-021005 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2012 Filed Feb 9, 2012 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,066 | $36.81 | $149,669.46 |
DisclosureSEC source: 0001209191-12-008688 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,108 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.81 (range $36.51 to $37.20). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007777 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007777 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,174 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,066 | $37.00 | $150,442.00 |
DisclosureSEC source: 0001209191-12-004852 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,008 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.84 to $37.10). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2011 Filed Jul 26, 2011 20:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $50.22 | $35,154.00 |
DisclosureSEC source: 0001209191-11-040959 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,074 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $50.22 (range $50.09 to $50.64). Read SEC document |
| July 25, 2011 Filed Jul 26, 2011 20:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $49.66 | $39,728.00 |
DisclosureSEC source: 0001209191-11-040959 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,774 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $49.66 (range $49.45 to $49.81). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039510 · doc4.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2021-07-12 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 9,531 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · derivative · entry 4 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,062 Underlying: Common Stock · 9,531 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,531 | $49.50 | $471,784.50 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,154 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 03, 2011 Filed Mar 4, 2011 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 9,531 | $18.93 | $180,421.83 |
DisclosureSEC source: 0001209191-11-015485 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 11,915 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 Underlying: Common Stock · 11,915 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,972 | $45.00 | $178,740.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,154 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,915 | $46.00 | $548,090.00 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,915 | $18.93 | $225,550.95 |
DisclosureSEC source: 0000875320-11-000019 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 23,828 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,446 Underlying: Common Stock · 23,828 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,914 | $44.00 | $524,216.00 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,914 | $43.60 | $519,450.40 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,040 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2011 Filed Feb 24, 2011 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 23,828 | $18.93 | $451,064.04 |
DisclosureSEC source: 0000875320-11-000018 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000015 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 20:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000015 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,126 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| January 21, 2011 Filed Jan 25, 2011 18:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,128 | $39.92 | $84,949.76 |
DisclosureSEC source: 0000875320-11-000004 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,960 F1 · kind: Transaction made pursuant to Mr. Sachdev's comany approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $39.92 (range $39.77 to $40.02). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 11,914 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,336 Underlying: Common Stock · 11,914 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,750 | $39.50 | $148,125.00 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,088 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,914 | $40.00 | $476,560.00 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,838 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 18, 2011 Filed Jan 20, 2011 17:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,914 | $18.93 | $225,532.02 |
DisclosureSEC source: 0000875320-11-000002 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2011 Filed Jan 13, 2011 18:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 451 | $37.66 | $16,984.66 |
DisclosureSEC source: 0000875320-11-000001 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,838 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 28, 2010 Filed Oct 29, 2010 15:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,750 | $38.50 | $182,875.00 |
DisclosureSEC source: 0000875320-10-000056 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,160 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 26, 2010 Filed Oct 28, 2010 18:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,534 | $37.50 | $170,025.00 |
DisclosureSEC source: 0000875320-10-000055 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,910 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 18, 2010 Filed Oct 20, 2010 16:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $36.50 | $36,500.00 |
DisclosureSEC source: 0000875320-10-000054 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,444 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Read SEC document |
| October 15, 2010 Filed Oct 18, 2010 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $35.00 | $35,000.00 |
DisclosureSEC source: 0000875320-10-000052 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,444 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000045 · edgar.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000011 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000011 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,983 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| October 22, 2009 Filed Oct 26, 2009 20:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0000875320-09-000092 · edgar.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2019-10-21 F1 · derivative.exercise_date: Stock option under 2006 Stock and Option Plan, vesting on 10/22/2014, subject to 20% acceleration upon receiving U.S. marketing approval for telaprevir; up to an additional 40% acceleration upon receiving U.S. approval for telaprevir if certain other performance goals are achieved; and 40% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of an additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| July 16, 2009 Filed Jul 20, 2009 19:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0000875320-09-000066 · edgar.xml · derivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2019-07-15 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09. Read SEC document |
| May 18, 2009 Filed May 19, 2009 18:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 783 | $28.44 | $22,268.52 |
DisclosureSEC source: 0000875320-09-000034 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Corp Affairs & Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,366 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $28.44 (range $28.12 to $28.92). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 61,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000011 · edgar.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Stock · 61,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,200 | $0.01 | $122.00 |
DisclosureSEC source: 0000875320-09-000011 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,366 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| November 18, 2008 Filed Nov 19, 2008 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 791 | $26.20 | $20,724.20 |
DisclosureSEC source: 0000875320-08-000088 · edgar.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Public Policy,Gov Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,166 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $26.20 (range $25.75 to $26.53). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.